Aaron Michel, Founder and VC - 1984 Ventures - podcast episode cover

Aaron Michel, Founder and VC - 1984 Ventures

Apr 27, 202248 minSeason 6Ep. 17
--:--
--:--
Download Metacast podcast app
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more

Episode description

The promise of angel-scale biotech: Learn More

Founder & VC Aaron Michel of 1984.vc on portfolio companies, Reggora, Faimarkit and Relevize and how they exemplify the firm’s approach to seed-stage investing. Aaron also gives Sal a mind-expanding suggestion on angel-scale biotech. Compelling & jargon-free!

Sponsored by Purdue University entrepreneurship and Peter Fasse, patent attorney at Fish & Richardson

  • Sal Daher, CFA Introduces Aaron Michel, Venture Capitalist at 1984.VC
  • Reggora: “...they're just enabling the lenders to do an appraisal almost in an Uberized fashion, in a much faster and much more efficient way than it used to be.”
  • Brian & Will of Reggora Sold $5 Million of Real Estate in their Senior Year at Boston University
  • A Dorm Room Business Helped the Founders of Reggora Discover a Scalable Business Opportunity
  • Fairmarkit Is Automating the Enterprise Procurement Process
  • Relevize – Helps Companies Sell Better via Channel Partners
  • Relevize Gives Channel Partners Digital Advertising Content and Then Monitors Performance
  • Aaron Michels Founded PathSource to Help People Find the Right Career
  • Sal’s Partner Bob Smith Was Not Cut Out for the Law But was a Natural Entrepreneur
  • “Both my parents are professors. They were both professors at Boston University. Both had started companies.”
  • CareerPath’s Pivot
  • How Aaron Michel Crossed Over from Being an Operator to Being a VC
  • “Ideally, you can choose your competitor set.”
  • “For B2B actually, we are open to investing pre-launch, as long as there's a product.”
  • Aaron Michel’s Mind-Expanding Suggestion for How Better to Address the Opportunities of Angel-Scale Biotech
  • “VCs tend to overvalue their advice and undervalue their introductions.”

Topics: founding story, competition, venture capital

 

For the best experience, listen in Metacast app for iOS or Android